Prediction of liver cancer treatment efficacy by CTC.
Not Applicable
Recruiting
- Conditions
- Cases of unresectable advanced hepatocellular carcinoma (HCC) for which treatment with immune checkpHepatocellular carcinoma, Immune checkpoint inhibitors, Circulating tumore cells
- Registration Number
- JPRN-jRCT1061230098
- Lead Sponsor
- Sugihara Takaaki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Select patients who meet all of the following criteria:
1) Diagnosed with hepatocellular carcinoma by imaging or histological examination.
2) Patients scheduled to receive treatment with immune checkpoint inhibitors.
3) Men and women aged 20 or older when obtaining consent.
Exclusion Criteria
Patients meeting any of the following criteria will not be included in this clinical study:
1) Patients with tumors originating from other organs.
2) Others deemed unsuitable as patients by the principal investigator for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood samples will be collected from patients with unresectable advanced hepatocellular carcinoma (HCC) before and after treatment with immune checkpoint inhibitors (regardless of treatment regimen or line), and circulating tumor cells (CTC) will be measured to verify the usefulness of CTC count in assessing treatment efficacy.
- Secondary Outcome Measures
Name Time Method